Fluzoparib
- Generic Name
- Fluzoparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04011124
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 113
- Registration Number
- NCT03509636
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT03075462
- Locations
- 🇨🇳
Beijing Cancer Hosptial, Beijing, Beijing, China
Food-Effect and Metabolism Study in Healthy Subjects
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03062982
- Locations
- 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03026881
- Locations
- 🇨🇳
The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT02575651
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳No.307 Hospital, Academy of Military Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.